Yttrium-90 (Y-90) resin microspheres
Phase 1Radiopharmaceutical
Yttrium-90 (Y-90) resin microspheres is one of 10 small molecule programs targeting Hypertrophy. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Hypertrophy
#DrugCompanyPhaseTrials
1Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Uroxatral
AAdvanz Pharma
Approved
Tylenol
KKenvue Brands
Approved
Ketalar
AAultman Health Foundation
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Botox
RRevance Therapeutics, Inc.
Phase 3
Ozempic
Novo NordiskPhase 2
Efanesoctocog Alfa
SanofiPhase 3
Salbutamol
GSKPreclinical
Yttrium-90 (Y-90) resin microspheres
MM.D. Anderson Cancer Center
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Radiopharmaceutical[2]
- Highest Phase
- Phase 1[1]
- Company
- MM.D. Anderson Cancer Center